Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Lebwohl M, et al. Among authors: chimenti s. N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824. N Engl J Med. 2015. PMID: 26422722 Free article. Clinical Trial.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. Among authors: chimenti s. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators. Bachelez H, et al. Among authors: chimenti s. Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4. Lancet. 2015. PMID: 26051365 Clinical Trial.
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K; TRANSIT Investigators. Paul C, et al. Among authors: chimenti s. Br J Dermatol. 2014 Feb;170(2):425-34. doi: 10.1111/bjd.12646. Br J Dermatol. 2014. PMID: 24116959 Free article. Clinical Trial.
Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.
Augustin M, Blome C, Paul C, Puig L, Luger T, Lambert J, Chimenti S, Girolomoni G, Kragballe K, Naessens D, Bergmans P, Smirnov P, Barker J, Reich K. Augustin M, et al. Among authors: chimenti s. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):294-303. doi: 10.1111/jdv.13823. Epub 2016 Aug 12. J Eur Acad Dermatol Venereol. 2017. PMID: 27515070 Clinical Trial.
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group. Dubertret L, et al. Among authors: chimenti s. Br J Dermatol. 2006 Jul;155(1):170-81. doi: 10.1111/j.1365-2133.2006.07344.x. Br J Dermatol. 2006. PMID: 16792770 Clinical Trial.
Biosimilars for psoriasis: clinical studies to determine similarity.
Blauvelt A, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, Skov L, Zachariae C, Young H, Prens E, Cohen A, van der Walt J, Wu JJ. Blauvelt A, et al. Among authors: chimenti s. Br J Dermatol. 2017 Jul;177(1):23-33. doi: 10.1111/bjd.15067. Epub 2017 May 28. Br J Dermatol. 2017. PMID: 27639072 Review.
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Among authors: chimenti s. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
Scalp psoriasis: European consensus on grading and treatment algorithm.
Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trüeb RM. Ortonne J, et al. Among authors: chimenti s. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1435-44. doi: 10.1111/j.1468-3083.2009.03372.x. Epub 2009 Jul 15. J Eur Acad Dermatol Venereol. 2009. PMID: 19614856
433 results